News coverage about Hutchison China MediTech Limited (NASDAQ:HCM) has trended somewhat positive on Sunday, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hutchison China MediTech Limited earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.8937285072695 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

HCM has been the topic of several recent analyst reports. Canaccord Genuity set a $30.00 price objective on shares of Hutchison China MediTech Limited and gave the company a “buy” rating in a research note on Tuesday, June 6th. BidaskClub downgraded shares of Hutchison China MediTech Limited from a “buy” rating to a “hold” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $28.00.

Hutchison China MediTech Limited (NASDAQ:HCM) opened at 25.59 on Friday. The company’s 50 day moving average is $25.34 and its 200 day moving average is $19.81. Hutchison China MediTech Limited has a 52 week low of $10.61 and a 52 week high of $26.50. The stock has a market cap of $3.11 billion, a P/E ratio of 241.42 and a beta of -2.00.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Insider Buying and Selling by Quarter for Hutchison China MediTech Limited (NASDAQ:HCM)

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with's FREE daily email newsletter.